دورية أكاديمية
Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma.
| العنوان: | Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma. |
|---|---|
| المؤلفون: | Yoon SE; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Shin SH; Geninus Inc., Seoul, Korea., Nam DK; Geninus Inc., Seoul, Korea., Cho J; Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Kim WS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea., Kim SJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea. |
| المصدر: | Cancer research and treatment [Cancer Res Treat] 2024 Jul; Vol. 56 (3), pp. 920-935. Date of Electronic Publication: 2024 Jan 16. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: The Association Country of Publication: Korea (South) NLM ID: 101155137 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2005-9256 (Electronic) Linking ISSN: 15982998 NLM ISO Abbreviation: Cancer Res Treat Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Seoul, Korea : The Association, |
| مواضيع طبية MeSH: | Lymphoma, Follicular*/genetics , Lymphoma, Follicular*/blood , Lymphoma, Follicular*/mortality , Lymphoma, Follicular*/drug therapy , Lymphoma, Follicular*/diagnosis , Circulating Tumor DNA*/genetics , Circulating Tumor DNA*/blood , Mutation* , Biomarkers, Tumor*/blood , Biomarkers, Tumor*/genetics , Feasibility Studies*, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Prognosis ; Rituximab/therapeutic use ; Aged, 80 and over ; Treatment Outcome |
| مستخلص: | Purpose: The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear. Materials and Methods: We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes. Results: Forty samples from patients receiving rituximab-containing immunochemotherapy were analyzed. Baseline sequencing detected mutations in all cases, with the major detected mutations being KMT2C (50%), CREBBP (45%), and KMT2D (45%). The concentration of ctDNA and tumor mutation burden showed a significant association with survival outcome. In particular, the presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them. Longitudinal analysis of ctDNA using serially collected plasma samples showed an association between persistence or reappearance of ctDNA mutations and disease relapse or progression. Conclusion: Analysis of ctDNA mutations in plasma at diagnosis might help predict outcome of disease, while analysis during follow-up may help to monitor disease status of patients with advanced FL. However, the feasibility of ctDNA measurement must be improved in order for it to become an appropriate and clinically relevant test in FL patients. |
| References: | Leuk Lymphoma. 2019 Sep;60(9):2237-2246. (PMID: 30774000) Lancet Oncol. 2015 Sep;16(9):1111-1122. (PMID: 26256760) J Clin Oncol. 2015 Aug 10;33(23):2516-22. (PMID: 26124482) Blood Adv. 2022 Mar 22;6(6):1651-1660. (PMID: 35086141) Haematologica. 2019 Jun;104(6):1202-1208. (PMID: 30573503) Bioinformatics. 2011 Nov 1;27(21):2987-93. (PMID: 21903627) Cancer Res Treat. 2022 Apr;54(2):597-612. (PMID: 34325497) Front Oncol. 2023 Feb 10;13:1109715. (PMID: 36845680) BMC Cancer. 2021 Aug 30;21(1):972. (PMID: 34461835) Blood. 2005 Dec 1;106(12):3725-32. (PMID: 16123223) Blood. 2018 Feb 8;131(6):595-604. (PMID: 29158360) Blood. 2008 Oct 15;112(8):3126-9. (PMID: 18628487) Haematologica. 2020 Feb 20;106(1):154-162. (PMID: 32079702) Genome Biol. 2016 Jun 06;17(1):122. (PMID: 27268795) Genome Res. 2010 Sep;20(9):1297-303. (PMID: 20644199) Ann Hematol. 2020 Jun;99(6):1293-1302. (PMID: 32296914) J Clin Oncol. 2014 Feb 20;32(6):579-86. (PMID: 24449238) Am J Hematol. 2020 Mar;95(3):316-327. (PMID: 31814159) J Clin Oncol. 2014 Sep 20;32(27):3059-68. (PMID: 25113753) Blood. 2004 Sep 1;104(5):1258-65. (PMID: 15126323) J Clin Oncol. 2019 Nov 1;37(31):2815-2824. (PMID: 31339826) Blood. 2015 Aug 13;126(7):851-7. (PMID: 26105149) J Clin Oncol. 2019 Dec 1;37(34):3300-3309. (PMID: 31461379) Blood Adv. 2022 Apr 26;6(8):2667-2680. (PMID: 35143622) J Clin Oncol. 2008 Oct 1;26(28):4579-86. (PMID: 18662969) Ann Oncol. 2016 Sep;27(suppl 5):v83-v90. (PMID: 27664263) CA Cancer J Clin. 2016 Nov 12;66(6):443-459. (PMID: 27618563) N Engl J Med. 2017 Oct 5;377(14):1331-1344. (PMID: 28976863) Nat Rev Dis Primers. 2019 Dec 12;5(1):83. (PMID: 31831752) Blood. 2016 May 19;127(20):2375-90. (PMID: 26980727) Lancet. 2013 Apr 6;381(9873):1203-10. (PMID: 23433739) Blood. 2019 Aug 29;134(9):761-764. (PMID: 31300404) Sci Adv. 2020 Dec 11;6(50):. (PMID: 33310847) J Cancer. 2021 Mar 5;12(9):2488-2497. (PMID: 33854610) Blood. 2014 May 8;123(19):2944-52. (PMID: 24591201) Cancer Res Treat. 2023 Jan;55(1):291-303. (PMID: 35240014) Nat Biotechnol. 2016 May;34(5):547-555. (PMID: 27018799) J Natl Cancer Inst. 2007 May 2;99(9):706-14. (PMID: 17470738) |
| معلومات مُعتمدة: | 2021R1A2C1007531 National Research Foundation of Korea; 2022R1F1A1064058 National Research Foundation of Korea |
| فهرسة مساهمة: | Keywords: Circulating tumor DNA; Follicular lymphoma; Mutations; Prognosis |
| المشرفين على المادة: | 0 (Circulating Tumor DNA) 0 (Biomarkers, Tumor) 4F4X42SYQ6 (Rituximab) |
| تواريخ الأحداث: | Date Created: 20240116 Date Completed: 20240717 Latest Revision: 20240724 |
| رمز التحديث: | 20240725 |
| مُعرف محوري في PubMed: | PMC11261198 |
| DOI: | 10.4143/crt.2023.869 |
| PMID: | 38228081 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2005-9256 |
|---|---|
| DOI: | 10.4143/crt.2023.869 |